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ORIGINAL ARTICLE
Attitudes of women towards products containing hormones (hormonal
contraceptives or hormone therapy): what changes from pre to
postmenopause?
Giovanni Grandi , Maria Chiara Del Savio, Valentina Boggio Sola, Francesca Monari, Chiara Melotti and
Fabio Facchinetti
Department of Medical and Surgical Sciences for Mother, Child and Adult, Azienda Ospedaliero-Universitaria di Modena, University of
Modena and Reggio Emilia, Modena, Italy
ABSTRACT
Introduction: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of
reproductive age in comparison with similar concerns of postmenopausal women in relation to
hormone therapy (HT).
Materials and methods: A questionnaire-based study was conducted in a population of 370
women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were eval-
uated using specific questions and Likert scales (-5 to þ5).Multivariate regression analyses were
adjusted for categories of HC/HT use (never, past and current).
Results: The most reported adverse effect associated with hormonal treatments was venous
thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p< .0001). According to
responses, hormonal treatments can increase the risk of developing venous thrombosis (OR
0.79; 95% CI 0.67–0.96, p¼ .004) and depression (OR 0.80; 95% CI 0.69–0.92, p¼ .002) more in
pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR
1.24: 95% CI 1.07–1.42, p¼ .003).The greatest oncological concern throughout life was about
breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the
risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19–1.75,
p¼ .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR
0.74; 95% CI 0.52–0.97, p¼ .03).
Conclusions: Our data suggest that our patients are primarily concerned about the effects of
hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and,
later in life, about their impact on weight gain, breast and ovarian cancer risk.
KEY MESSAGES
1. Young patients are primarily concerned about the effects of hormonal treatments on ven-
ous thrombosis, mood, breast cancer and cervical cancer risk.
2. Older patients are primarily concerned about the effects of hormonal treatments on weight
gain, breast and ovarian cancer risk.
3. The greatest oncological concern throughout life was about breast cancer.
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Introduction
Nowadays, hormonal treatments are commonly used
by millions of women worldwide. Most women use at
least one hormone therapy at some point of their life
in the developed world, including hormonal contra-
ceptives (HC) and hormone therapy (HT) after meno-
pause. Despite being widely-prescribed, users are still
doubtful about synthetic hormones, both in pre- and
post-menopause.
More than 9 million premenopausal women using
contraception relied on the contraceptive pill in 2014
in the US [1,2]. In Europe, considering countries such
as France, Spain, Germany, Italy and United Kingdom,
around 22 million out of 72 million premenopausal
women are currently using of contraceptive pill [3],
with rates of usage varying from 35% in Spain to 63%
in Germany [4]. Available contraceptives make it pos-
sible to choose between combined formulations based
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on oestrogens and progestin and those containing
only a progestin. The former varies in doses and types
of oestrogens or progestins, as well as route of admin-
istration (pill, patch, vaginal ring, subcutaneous
implant, injection or intrauterine device). HC use in
premenopausal women plays not only the role of pre-
venting unintended pregnancies [5]: the physiological
actions of the oestrogens and progestins also provide
important non-contraceptive benefits, including treat-
ment of common gynaecological and non-gynaeco-
logical medical conditions [6].
Indications for hormone therapy are not limited to
women of reproductive age: hormones are also widely
used in post-menopausal women, with different thera-
peutic schemes. For example, HT is used to relieve
menopausal symptoms [7]. It is the principal therapy
for urogenital and vasomotor symptoms of meno-
pause, offering multiple additional beneficial effects
on women’s health, such as prevention and manage-
ment of osteoporosis [8] and dementia [9,10].
Furthermore, as confirmed by the Women’s Health
Initiative (WHI) study, it can exert a protective effect
on the cardiovascular system if started at the begin-
ning of menopause [7,8] and can also improve sleep
and mood disorders [8–10]. There are different formu-
lations for postmenopausal HT: oestrogen only (indi-
cated for women who have previously undergone a
hysterectomy), oestrogen combined with progestin
(indicated for women who have not previously under-
gone a hysterectomy), and “progestin-free” drugs,
such oral tibolone and combinations of oestrogen
with bazedoxifene (Tissue Selective Oestrogen
Complex) [11]. HT can be taken at different doses and
in different ways: orally, as a patch, or as a transder-
mal [8].
The indications for hormone therapies, both pre-
and post-menopausal, are many, as are the concerns
about them. Deepening the conception that women
of all ages have about hormone therapies can help in
the counselling that should guide the personalized
choice of drugs. For these reasons, in this study we
want to investigate the current knowledge of the ben-
efits and risks of hormonal treatments by comparing
responses to an identical set of questions from




This is a cross-sectional, observational study performed
from December 2019 to May 2020 at the Department
of Obstetrics and Gynaecology at Azienda Ospedaliero-
Universitaria of Modena (Italy) in premenopausal or
postmenopausal subjects evaluated at a routine
visit.Included subjects were a group of women with no
previous oncological diseases evaluated for a routine
visit at the general gynecological service of the hospital
(“Ambulatorio Divisionale”). This service is where gen-
eral practitioners send patients for routine gyneco-
logical examinations. Therefore, they are in general
healthy women who did not present particular gyneco-
logical disorders or complaints. Menopausal status was
classified as amenorrhoea for over 12months.
Evaluated variables
After detailed counselling about the study, the women
who chose to participate signed an informed consent
form. Once included in the study, women were given
an identical questionnaire depending on the group
they belonged to (pre- or post-menopause) (i.e. use of
HC or HT) (Supplemental Table 1). The questionnaires
were self-administered before the medical consult-
ation, without intervention of the researchers collect-
ing the data. During the gynaecological examination,
clinical data from the included women were collected:
age, parity, and number of vaginal or caesarean births,
abortions, and gynaecological surgeries previ-
ously performed.
For both groups of women, questionnaires collected
data on the type of HC/HT eventually used, the brand
name of the product, use (current, past, never used)
and the duration of use (months/years). Women were
asked to evaluate how much in their opinion HC/HT
could affect the risk of developing some forms of can-
cer (breast, ovary, colon, uterine body, uterine cervix) or
diseases (venous thrombosis, breast cysts, cardiovascu-
lar diseases, depression), or other classical possible side-
effects (headache, weight gain, reduced sexual desire,
vaginal dryness, increased appetite, mood swings) using
a Likert scale from 5 to þ5. For cancers and diseases,
5¼ reduces the risk of onset, 0¼ neutral effect,
þ5¼ increases the risk of onset, while for symptoms,
5¼worsens with HT, 0¼neutral effect,
þ5¼ improves with HT (Supplemental Table 1). For the
final analyses, included women were divided according
to their HC and/or HT use in 3 categories: 1) never
users (women who had never used HC and HT) 2) past
users (women using HC and/or HT in the past) or 3)
current users (women who are taking HC or HT at the
moment of the study inclusion).
An English translation of the specific questionnaires
used in this study are reported in Supplemental Table
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1. The types of questions were obtained from a previ-
ously published questionnaire-based study undertaken
in the same area of Italy [12] and another study
recently published by our research group [13].
Ethics and statistics
The study was designed and conducted in full accord-
ance with the World Medical Association Declaration
of Helsinki, as revised in 2002. The ethics committee
of Modena approved the use of the questionnaires in
our Department (reference 36/17) and a specific
informed consent was obtained from each woman for
the use of her sensitive data in research analysis.
The questionnaire responses of pre- and post-
menopausal women were analyzed and compared.
The frequency of answers in the different groups was
calculated. When necessary, the prevalence was com-
pared using contingency tables. Comparisons of con-
tinuous variables between groups were performed
using Student’s t test. Multivariate logistic and mul-
tiple regression analysis were used to investigate risk
factors associated with different perceptions in pre or
postmenopause, adjusting for confounding such as
categories of HC/HT use (never, past and current): can-
didate variables were included if significant on univari-
ate analysis or clinically relevant. Multiple regression
models were used to study the impact of women age.
Statistical analysis was performed using the statistical
package StatView (v 5.01.98; SAS Institute Inc, Cary,
NC, USA). Correlations were considered significant at a
p-value <.05. Continuous results are expressed as
mean± standard deviation (SD).
Sample size calculation
Assuming a pooled SD of 1 unit, the study was deter-
mined to require a sample size of 128 women for
each group (giving a total sample size of 256,
assuming equal group sizes) to achieve a power of
80% and a level of significance of 5% (two sided), for
detecting a true difference in means of 0.35 units in
Likert Scale values between different groups.
Results
Study group
A population of 370 women (mean age:
42.7 ± 13.8 years, range 19.0–74.0 years) was included
in the study and completed the specific question-
naires. Of these women, 198 (53.5%) were premeno-
pausal, while 172 (46.5%) were postmenopausal. The
features of the two groups and their current/past use
of HC and/or HT are reported in Table 1. According to
categories about HC/HC use (see above), included
women can be divided in n¼ 84 never users, n¼ 202
past users and n¼ 84 current users.
Side effects of hormonal treatments
Knowledge of effects of hormonal treatment on dis-
ease development and side effects
The answers to the questions “How much can HC/HT
increase or reduce the risk of developing these dis-
eases?” and “How much can HC/HT improve or worsen
these symptoms?” are reported in Table 2, for the
whole study group and for pre- and post-menopausal
women separately.
The most reported adverse effect associated with
hormonal treatments was venous thrombosis
(1.4 ± 0.1), especially for HC use in premenopausal
women (p<.0001). Similarly, a negative effect on car-
diovascular diseases is reported more frequently in
premenopausal women (p¼.0003) (Table 2). On the
other hand, a possible negative impact on depression
was reported only for HC use in premenopausal
women (p<.0001) (Table 2).
Table 1. Features of n¼ 370 women included in the study.
Premenopausal (n¼ 198) Postmenopausal (n¼ 172) p
Age (years old) 32.3 ± 8.9 54.7 ± 7.1 <.0001
Nulliparous (n, %) 144 (72.7%) 26 (15.1%) <.0001
HC use (n, %)
Present users 65/198 (32.8%) /
Past users 95/198 (48.0%) 117/172 (68.0%)
Never 38/198 (19.2%) 55/172 (32.0%)
Actual duration of HC use (years) 3.6 ± 3.5 /
Past duration of HC use (years) 4.7 ± 4.4 7.5 ± 7.7
HT use (n, %)
Present users / 19/172 (11.0%)
Past users / 23/172 (13.4%)
Never / 130/172 (75.6%)
Actual duration of HT use (years) / 1.7 ± 1.8
Past duration of HT use (years) / 3.9 ± 4.7
HC: hormonal contraception; HT: postmenopausal hormone therapy.
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Interestingly, the most significant side effects of
HC/HT use were headache (0.4 ± 0.1) and mood swings
(0.4 ± 0.1). The impact of HT on weight increase was
significantly overestimated by postmenopausal women
(p¼ .02) (Table 2).
Categories of HC/HT use (never, past, current users)
were not linked to knowledge of effects of hormonal
treatment on disease development and side effects
(p>.05), both in pre and in postmenopause.
Multivariate analysis
Menopausal status. Results of the multivariate ana-
lysis are reported in Table 3 and confirm the pre-
sented results. According to the responses, hormonal
treatments can increase the risk of developing venous
thrombosis and depression more in premenopausal
women, while they increase the risk of weight gain
more in post-menopause.
Age. Calculations based on the age of included
women confirmed the results of menopausal status. In
a multiple regression model including all of the eval-
uated diseases, age was significantly inversely associ-
ated with the response to the question “HC/HT can
increase the risk of developing venous thrombosis
(coefficient 1.13, p¼.005) and depression” (coefficient
1.16, p¼ .001) (i.e. greater belief that there is an
increase in risk in younger women).
In a multiple regression model including all pos-
sible symptoms associated with treatment, age was
significantly associated with the response to the ques-
tion “HC/HT can increase the risk of weight increase”
(coefficient þ0.87, p¼.01) (i.e. greater belief that there
is an increase in risk in older women).
Oncological effects of hormonal treatments
Knowledge of effects of hormonal treatments on
cancer development
The answers to the question “How much can HT
increase or reduce the risk of developing these can-
cers?” are reported in Table 4. In general, the greatest
concern was about breast cancer (0.9 ± 0.1), followed
by uterine cervix cancer (0.4 ± 0.1) and uterine body
cancer (0.2 ± 0.1) (Table 4). The protective effect on
ovarian cancer was only significantly reported con-
cerning HC in premenopausal women (p<.0001). Also,
the perceived protective role of HC or HT on colorec-
tal cancer was more evident for HC in premenopausal
women (p¼.03).
Categories of HC/HT use (never, past, current users)
were not linked to knowledge of effects of hormonal
Table 2. Mean ± Standard Error (Likert scale from -5 to þ5) sort in descending order to the questions “How much does HC/HT
increase or reduce the risk of developing these diseases?” and “How much does HC/HT improve or worsen these symptoms?” for
the whole study group and for premenopausal vs. postmenopausal women, separately.
How much does HC/HT increase or reduce the risk of developing these diseases?
Total group (n¼ 370) Premenopausal women (n¼ 198) Postmenopausal women (n¼ 172) p
Venous thrombosis 1.4 ± 0.1 1.8 ± 0.2 0.8 ± 0.2 <.0001
Breast cysts 0.6 ± 0.1 0.5 ± 0.1 0.7 ± 0.2 .33
Cardiovascular diseases 0.5 ± 0.1 0.9 ± 0.1 0.1 ± 0.2 .0003
Depression 0.0 ± 0.1 0.6 ± 0.1 0.6 ± 0.2 <.0001
How much does HC/HT improve or worsen these symptoms?
Headache 0.4 ± 0.1 0.3 ± 0.2 0.5 ± 0.2 .37
Mood swings 0.4 ± 0.1 0.5 ± 0.2 0.1 ± 0.2 .15
Weight increase 0.3 ± 0.1 0.0 ± 0.2 0.7 ± 0.2 .02
Increased appetite 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.2 .82
Vaginal dryness 0.0 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 .36
Reduction of libido 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 .78
Bold characters represent statistically significant results (p < .05).
Table 3. Multivariate logistic regression analyses.
Perceived OR of HC/HT can increase the risk of developing these diseases
(postmenopausal vs. premenopausal women) p
Venous thrombosis 0.79 [0.67–0.93] .004
Depression 0.80 [0.69–0.92] .002
Perceived OR of HC/HT can worsen this symptom
(postmenopausal vs. premenopausal women)
Weight increase 1.24 [1.07–1.42] .003
Perceived OR of HC/HT can increase the risk of developing these cancers
(postmenopausal vs. premenopausal women)
Ovarian cancer 1.44 [1.19–1.75] .0002
Uterine cervix cancer 0.74 [0.52–0.97] .03
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treatments on cancer development (p>.05), with the
only exception of the effect on ovarian cancer: current
users were significantly more reporting a protective
effect (p¼.001).
Multivariate analysis
Menopausal status. Results of the multivariate ana-
lysis are reported in Table 3. There is the perception
that hormonal treatments increase the risk of develop-
ing ovarian cancer more in postmenopausal women,
whereas they increase the risk of uterine cervix cancer
more in premenopausal women.
Age of women. In a multiple regression model includ-
ing all evaluated cancers, age was significantly associ-
ated with the response to the question “HC/HT can
increase the risk of developing ovarian cancer” (coeffi-
cient 2.18, p<.0001) (i.e. greater belief that there is an
increase in risk in older women), and inversely associ-
ated with the response to the question regarding
“developing uterine cervix cancer” (coefficient 1.95,
p¼.002) (i.e. greater belief that there is an increase in
risk in younger women).
Discussion
Overall results
The results of the present study should be used to
guide counselling when prescribing hormonal treat-
ments, such as HCs in premenopausal women or HTs
in postmenopausal women. Addressing patients’ belief
in false myths and trying to overcome their more or
less justified worries is one of the most important
tasks in the therapeutic prescription process today,
especially for hormonal treatments.
Our original results demonstrate that premeno-
pausal women tend to overestimate the negative
impact of HC on venous thromboembolism and on
depression in comparison to the views of post-meno-
pausal women surrounding HT. Conversely,
postmenopausal women are much more concerned
about the possible weight gain associated with HT.
Regarding the oncological risk of these therapies,
we have demonstrated that fear of breast cancer is
similar in pre and postmenopausal women, presenting
the most intense life-long oncological worry.
The protective effect on ovarian cancer was cor-
rectly reported only by premenopausal women, sur-
rounding HC use, while the protective role of
hormonal treatment on colorectal cancer was more
evident for HC in premenopausal women (but was
also true for HT in postmenopausal women). In par-
ticular, we have shown a direct increase in fear sur-
rounding the use of hormones with age, for ovarian
cancer (more perceived risk in older women), and an
inverse relationship for uterine cervix cancer (more
perceived risk in younger women).
Interpretation
Adequate counselling surrounding hormonal treat-
ments during life may help women recognize the
health benefits and risks of these drugs [12]. In daily
practice, myths and taboos regarding side effects and
long-term consequences of hormonal treatment use
on women’s health need to be fully addressed. This
partial and summary information transcends conti-
nents and stage of life (pre- vs. post-menopause), and
is shared by both highly educated women and women
with little education [12]. Attitudes of health-care pro-
fessionals (HCPs) may contribute significantly to wom-
en’s knowledge, depending on their ability to share
conclusive information with potential users of hormo-
nal treatments.
Most vague complaints attributed to hormonal
treatments can be explained by women’s negative
expectations (the nocebo phenomenon) or by the
high background prevalence of such complaints [14].
Moreover, it has been demonstrated that the elderly
may be more susceptible to the nocebo phenomenon
than the young [15].
Table 4. Mean± Standard Error (Likert scale from -5 to þ5) sort in descending order to the question “How much does HC/HT
increase or reduce the risk of developing these cancers?” for the whole study group and for the whole study group and for pre-
menopausal vs. postmenopausal women, separately.
How much does HC/HT increase or reduce the risk of developing these cancers?
Total group (n¼ 370) Premenopausal women (n¼ 198) Postmenopausal Women (n¼ 172) p
Breast cancer 0.9 ± 0.1 0.7 ± 0.2 1.1 ± 0.2 .21
Uterine cervix cancer 0.4 ± 0.1 0.2 ± 0.1 0.5 ± 0.2 .33
Uterine body cancer 0.2 ± 0.1 0.0 ± 0.2 0.5 ± 0.2 .04
Ovarian cancer 0.0 ± 0.1 0.6 ± 0.1 0.6 ± 0.2 <.0001
Colorectal cancer 0.2 ± 0.1 0.4 ± 0.1 0.1 ± 0.2 .03
Bold characters represent statistically significant results (p < .05).
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Conventional wisdom has been to counsel women
thoroughly about hormonal treatments. This practice
assumes that anticipatory counselling about side
effects will improve acceptability and compliance.
However, nocebo phenomenon studies in other areas
of medicine suggest that such counselling may have a
paradoxical effect: by raising these issues, clinicians
may create or aggravate side effects that would not
otherwise have occurred [15].
Data on women’s knowledge of the effects of hor-
monal treatments (both HC and HT) on health and
wellbeing are generally very scarce in the literature.
Our results concerning venous thrombosis risk are sur-
prising: the perceived risk is more evident in pre- than
in post-menopause. Although venous thrombosis inci-
dence naturally increases during the reproductive
period of a woman’s life, the difference associated
with HC use during this period is relatively low when
looking at the whole lifespan; however, the risk during
menopause is considerably higher, especially during
HT treatment [16,17].
It is well known that hormones and their fluctuations
in the natural menstrual cycle are frequently associated
with mood alterations: in the context of negative
reports regarding HC and mood, the findings of high-
quality prospective studies show that the effect is negli-
gible and the effect of hormones on mood is individual
[18]. However, as we have demonstrated, the problem
of depression associated with hormonal treatments is
more felt in young women than older ones.
Communicating cancer risk information is relevant
to a number of HCPs. Moreover, information about
risk can also be important in motivating individuals to
engage in cancer screening. Reliable epidemiological
assessment of any association of hormone therapy use
with cancer requires large numbers and careful control
of all potential sources of appreciable bias.
HC use has demonstrated a clear and significant
protective effect on the risk of ovarian cancer. The risk
of endometrial cancer is reduced by about 50% in
ever users of HCs, a benefit which is greater with
increasing duration of use. An association has been
found between increased risk of uterine cervical can-
cer and long-term HC use. How breast cancer risk
changes during HC use remains unclear: if an
increased risk exists, it is mainly confined to current
and very young users of HC [19]. Conversely, from the
introduction of post-menopausal HT, there has been
great concern that it may increase the risk of breast
cancer, particularly in the case of combined HT includ-
ing a progestin [20,21].Colorectal cancer is the most
frequent neoplasm in non-smokers of both sexes
combined in Western countries, and HT use seems to
reduce its risk [22]. On the other hand, ovarian cancer
risk is significantly increased in current users of HT,
even in those with less than 5 years of HT use [23].
Breast cancer is the most common cancer diag-
nosed among women in 140 of 184 countries.
According to the 2012 report of the GLOBOCAN
Project, breast cancer accounts for 25% (1.67 million)
of all new cancer cases [24]: our results demonstrate
that the perception of its risk is the highest, and
remains steady throughout the entire lifespan. Breast
cancer affects women of all ages, with most cases
diagnosed in women older than 50 years and women
younger than 45 years only accounting for <10% of all
cases. Our results confirm that breast cancer risk per-
ception and screening behaviour are between the
most important factors that must be addressed during
gynaecological consultations [25]. This is true although
how its risk varies during use of hormonal treatments
is not fully understood [26,27], also in women with a
family history [28].
Conversely, cervical cancer is most frequently diag-
nosed in women between the ages of 35 and 44, and
for this reason it is not surprising that the correlation
is more reported by premenopausal women in our
study [19]. Cervical cancer is caused by HPV infection,
and exposure to genital HPV is not independent of HC
use [19]. Women using HC are more likely to be
exposed to HPV than those using barrier contraceptive
methods or not having sexual intercourse.
Numerous studies of interventions providing tail-
ored information about cancer risk or possible screen-
ing, delivered by print or computer, have been
conducted in the last decade. However, there is no
evidence that the tailoring of these messages affects
secondary prevention measures, such as the uptake of
breast or uterine cervix cancer screening [29]. In con-
clusion, as consultation time is scarce, our messages
surrounding hormone therapies must be focussed on
the perceptions of the patients.
Limitations
There were several limitations of this survey, including
its cross-sectional study design and the simplified
form of the questionnaire used in both pre- and post-
menopausal women. In addition, our sample size cal-
culation was able to recognize a true difference in
means of 0.35 unit in some Likert Scale values
between different groups, pre vs. postmenopausal
women. However, it would be not large enough to
enable the possible detection of negligible differences
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<0.35 point between different groups. Our results
have not been corrected for family history of the pre-
sented diseases, for educational levels of women and
for residual ovarian activity (in premenopausal women
with premature ovarian failure) which could strongly
affect their attitudes. The strengths of this study
include the in-depth questions and the availability of
a large volume of data from participants. Moreover, it
is the first published study that evaluates similar ques-
tions and perceptions throughout a woman’s
whole life.
Conclusions
The results of the present study should be used to
guide our counselling activity when prescribing hor-
monal treatments in women. Addressing false myths
and trying to overcome unjustified worries is one of
the most important tasks in therapeutic prescription
today. The benefit/risk calculus of HC and HT tips
decidedly towards benefits for most women. Our data
suggest that our patients are primarily interested in
the effect of hormonal treatments on venous throm-
bosis, mood, breast and cervical cancer risk, and, later
in life, impact on weight gain, breast cancer and ovar-
ian cancer risk.
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